Senti Biosciences Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SNTI | GDTC | INAB | ATORX.ST | IMNN | ARTV | |
|---|---|---|---|---|---|---|
| Market cap | 6.79M | 10.61M | 9.18M | 38.18M | 5.09M | 206.32M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.2 | -5.9 | -1.0 | -0.1 | -0.5 | -2.1 |
| Price/book | -1.6 | 2.7 | 0.5 | 0.3 | 2.2 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −90.82% | −56.42% | −43.92% | −99.44% | −77.02% | +22.67% |
| Today | −0.73% | −2.31% | −2.02% | 0.00% | +0.78% | +0.48% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SNTI news ›Senti Biosciences Adjourns Merger Vote, Seeking Additional Stockholder Support
The Clinical Trial Vanguard Senti Biosciences Adjourns Merger Vote, Seeking Additional Stockholder Support A stockholder vote is stalling a merger, and Senti Biosciences does not yet have enough support to push it throug
Programmable Cell Therapy Market Is Going to Boom |CRISPR Therapeutics AG, Senti Biosciences, Inc., Cellectis S.A.
openpr.com Programmable Cell Therapy Market Is Going to Boom |CRISPR Therapeutics AG, Senti Biosciences, Inc., Cellectis S.A. Press release from: Coherent Market Insights Permanent lin
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- clinicaltrialvanguard.com1
- openpr.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.